Zusammenfassung
Die Angiogenese ist ein physiologischer und lebensnotwendiger Prozess. Unter bestimmten Umständen kann dieser aber auch Ausdruck krankhafter Mechanismen sein. Man spricht dann von pathologischen Neovaskularisationen. Diese können im Rahmen neoplastischer Prozesse auftreten. In den meisten Fällen handelt es sich aber um ein reaktives Ereignis auf ein sich veränderndes Milieu. Hierzu zählen insbesondere hypoxische und entzündliche Vorgänge. Neovaskularisationen am Auge wirken sich durch die besondere Anatomie und Funktion des Organs meistens funktionsbeeinträchtigend aus und können letztendlich zur Erblindung oder Verlust des Auges führen. Zahlreiche Studien weisen den Faktor VEGF (»vascular endothelial growth factor«) als potenten Stimulator okulärer Neovaskularisationen aus.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bartz-Schmidt KU. Ziemssen F (2008) Intravitreale Pharmakotherapie. Schattauer, Stuttgart New York
Bell C, Lynam E, Landfair DJ Janjic N, Wiles ME (1999) Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 35:533–542
Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, Saperstein DA, Gupta A, Stout JT, Macko J, DiBartolomeo R, Wei LL. (2006) Adenoviral vector-delivered pigment epitheliumderived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 17:167–176
Danis R, Criswell M, Orge F, Wancewicz E, Stecker K, Henry S, Monia BD (2003) Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization. Curr Eye Res 26:45–54
Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf JL, Gill SC, Bendele RA. (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17:1503–1510
Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, Fandl JP, Lee F, Carver S, McNay J, Bailey K, Ramakanth S, Hutabarat R, Huang TT, Radziejewski C, Yancopoulos GD, Stahl N (2003) Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 9: 47–52
Ferrara N, D’Amico L, Shams N, Lowman H, Kim R (2006) Development of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:850–870
Gebauer M, Skerra A (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 3:245–255
Grisanti S, Tatar O (2008) The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Ret Eye Resh 27:372–390
Ishida S, Usui T, Yamashiro K Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP (2003) VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 44: 2155–2162
Kwak N, Okamoto N, Wood JM, Campochiaro PA (2000) VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158–3164
Kyowa Hakko Kogyo KK (2003) VEGF receptor Flt-1 monoclonal US6617160;
Mori K, Ando A, Gehlbach P, Nesbitt D, Takahashi K, Goldsteen D, Penn M, Chen CT, Mori K, Melia M, Phipps S, Moffat D, Brazzell K, Liau G, Dixon KH, Campochiaro PA (2001) Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 159:313–3201
Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA; CLEAR-AMD 1 Study Group. (2006) A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:1522.e1–1522
Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, Wadsworth SC, Scaria A (2009) Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 16:10–16
Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ (2003) Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9:210–216
Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjić N (1998) 2’-Fluoropyrimidine RNAbased aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF 165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273: 20556–20567
Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, Berghaus A, Dellian M (2008) Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 122:452–460
Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 109, 227–241
The CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration, Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration, N Engl J Med 364(20):1897–908
Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW (1999) Detection and plasma pharmacokinetics of an antivascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732: 203–212
Usui T, Ishida S, Yamashiro K Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP (2004) VEGF 164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 45:368–374
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Grisanti, S., Lüke, J., Peters, S. (2011). Anti-VEGF-Therapie: Grundlagen und Substanzen. In: Altersabhängige Makuladegeneration. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20870-6_14
Download citation
DOI: https://doi.org/10.1007/978-3-642-20870-6_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-20869-0
Online ISBN: 978-3-642-20870-6
eBook Packages: Medicine (German Language)